U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C18H15BrF2N4O2
Molecular Weight 437.238
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of NELOTANSERIN

SMILES

COC1=CC=C(NC(=O)NC2=CC=C(F)C=C2F)C=C1C3=C(Br)C=NN3C

InChI

InChIKey=COSPVUFTLGQDQL-UHFFFAOYSA-N
InChI=1S/C18H15BrF2N4O2/c1-25-17(13(19)9-22-25)12-8-11(4-6-16(12)27-2)23-18(26)24-15-5-3-10(20)7-14(15)21/h3-9H,1-2H3,(H2,23,24,26)

HIDE SMILES / InChI

Molecular Formula C18H15BrF2N4O2
Molecular Weight 437.238
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Nelotanserin is a potent, selective 5-HT(2A) inverse agonist. Originally called ADP-125, the compound was developed by Arena Pharmaceuticals as a treatment for insomnia, but failed efficacy measures for this indication in Phase 2. In 2015, Axovant Sciences licensed this compound for development, renamed it nelotanserin, and began evaluating it in dementia with Lewy bodies (DLB). Both radioligand binding and functional inositol phosphate accumulation assays suggest that nelotanserin has low nanomolar potency on the 5-HT(2A) receptor with at least 30- and 5000-fold selectivity compared with 5-HT(2C) and 5-HT(2B) receptors, respectively. Nelotanserin dosed orally prevented (+/-)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI; 5-HT(2A) agonist)-induced hypolocomotion, increased sleep consolidation, and increased total nonrapid eye movement sleep time and deep sleep, the latter marked by increases in electroencephalogram (EEG) delta power. Nelotanserin has been used in trials studying the treatment of Lewy body dementia, visual hallucinations, dementia with Lewy bodies, and REM sleep behavior disorder.

Approval Year

Targets

Targets

PubMed

PubMed

TitleDatePubMed
Nelotanserin, a novel selective human 5-hydroxytryptamine2A inverse agonist for the treatment of insomnia.
2010 Jan
Discovery of 1-[3-(4-bromo-2-methyl-2h-pyrazol-3-yl)-4-methoxyphenyl]-3-(2,4-difluorophenyl)urea (nelotanserin) and related 5-hydroxytryptamine2A inverse agonists for the treatment of insomnia.
2010 Mar 11
Patents

Sample Use Guides

Lewy Body Dementia: Nelotanserin 40mg then nelotanserin 80 mg; once daily, oral, 20-mg tablets
Route of Administration: Oral
Results from IP accumulation assays suggest that Nelotanserin is a potent 5-HT2A full inverse agonist (IC50=1.7 nM), a moderately potent 5-HT2C partial inverse agonist (IC50=79 nM) (maximal response was 62% of the response obtained for the reference inverse agonist clozapine), and a weak 5-HT2B inverse agonist (IC50=791 nM). Nelotanserin displays high affinity for recombinant human 5-HT2A receptors (Ki=0.35 nM), moderate affinity for human 5-HT2C receptors (Ki=100 nM), and low affinity for human 5-HT2B receptors (2000 nM) stably expressed in HEK293 cells. The results suggest that Nelotanserin has a 262-fold higher affinity for human 5-HT2A than 5-HT2C receptors and a 6610-fold higher affinity for human 5-HT2A than 5-HT2B receptors.
Substance Class Chemical
Created
by admin
on Sat Dec 16 17:58:22 GMT 2023
Edited
by admin
on Sat Dec 16 17:58:22 GMT 2023
Record UNII
4ZA73QEW2P
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
NELOTANSERIN
INN   USAN  
INN   USAN  
Official Name English
APD125
Code English
nelotanserin [INN]
Common Name English
1-(3-(4-BROMO-2-METHYL-2H-PYRAZOL-3-YL)-4-METHOXYPHENYL)-3-(2,4- DIFLUOROPHENYL)UREA
Systematic Name English
1-[3-(4-Bromo-1-methyl-1H-pyrazol-5-yl)-4-methoxyphenyl]-3-(2,4-difluorophenyl)urea
Systematic Name English
UREA, N-(3-(4-BROMO-1-METHYL-1H-PYRAZOL-5-YL)-4-METHOXYPHENYL)-N'-(2,4-DIFLUOROPHENYL)-
Systematic Name English
NELOTANSERIN [USAN]
Common Name English
APD-125
Code English
Classification Tree Code System Code
NCI_THESAURUS C66885
Created by admin on Sat Dec 16 17:58:22 GMT 2023 , Edited by admin on Sat Dec 16 17:58:22 GMT 2023
Code System Code Type Description
SMS_ID
300000034287
Created by admin on Sat Dec 16 17:58:22 GMT 2023 , Edited by admin on Sat Dec 16 17:58:22 GMT 2023
PRIMARY
FDA UNII
4ZA73QEW2P
Created by admin on Sat Dec 16 17:58:22 GMT 2023 , Edited by admin on Sat Dec 16 17:58:22 GMT 2023
PRIMARY
DRUG BANK
DB12555
Created by admin on Sat Dec 16 17:58:22 GMT 2023 , Edited by admin on Sat Dec 16 17:58:22 GMT 2023
PRIMARY
WIKIPEDIA
NELOTANSERIN
Created by admin on Sat Dec 16 17:58:22 GMT 2023 , Edited by admin on Sat Dec 16 17:58:22 GMT 2023
PRIMARY
NCI_THESAURUS
C83996
Created by admin on Sat Dec 16 17:58:22 GMT 2023 , Edited by admin on Sat Dec 16 17:58:22 GMT 2023
PRIMARY
INN
9109
Created by admin on Sat Dec 16 17:58:22 GMT 2023 , Edited by admin on Sat Dec 16 17:58:22 GMT 2023
PRIMARY
ChEMBL
CHEMBL598172
Created by admin on Sat Dec 16 17:58:22 GMT 2023 , Edited by admin on Sat Dec 16 17:58:22 GMT 2023
PRIMARY
CAS
839713-36-9
Created by admin on Sat Dec 16 17:58:22 GMT 2023 , Edited by admin on Sat Dec 16 17:58:22 GMT 2023
PRIMARY
MESH
C546600
Created by admin on Sat Dec 16 17:58:22 GMT 2023 , Edited by admin on Sat Dec 16 17:58:22 GMT 2023
PRIMARY
EPA CompTox
DTXSID40232868
Created by admin on Sat Dec 16 17:58:22 GMT 2023 , Edited by admin on Sat Dec 16 17:58:22 GMT 2023
PRIMARY
PUBCHEM
11683556
Created by admin on Sat Dec 16 17:58:22 GMT 2023 , Edited by admin on Sat Dec 16 17:58:22 GMT 2023
PRIMARY
USAN
UU-15
Created by admin on Sat Dec 16 17:58:22 GMT 2023 , Edited by admin on Sat Dec 16 17:58:22 GMT 2023
PRIMARY
Related Record Type Details
TARGET->INVERSE AGONIST
Was under development for the treatment of insomnia. Development was halted in December 2008 because the substance did not meet the trial's effectiveness endpoints.recently, nelotanserin has been repurposed for the treatment of Lewy body disease.
Related Record Type Details
ACTIVE MOIETY